Dashboard
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 4.68 times
- The company has been able to generate a Return on Equity (avg) of 0.14% signifying low profitability per unit of shareholders funds
Negative results in Sep 26
Stock is technically in a Bearish range
Risky - Negative EBITDA
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
INR 198 Cr (Micro Cap)
NA (Loss Making)
40
0.00%
-0.30
-12.35%
0.34
Total Returns (Price + Dividend) 
Latest dividend: 0.05 per share ex-dividend date: Sep-11-2020
Risk Adjusted Returns v/s 
Returns Beta
News

Nectar Lifescience Ltd is Rated Strong Sell
Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 18 November 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Nectar Lifescience Ltd Reports Negative Financial Trend Amidst Mixed Quarterly Performance
Nectar Lifescience Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a marked deterioration in its financial trend for the quarter ended September 2026. Despite posting its highest quarterly PAT in recent history, the company’s overall financial health has weakened, with key profitability and efficiency metrics showing significant contraction compared to historical averages.
Read More
Nectar Lifescience Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight
At Rs 9.82, sellers were still queuing — but there were no buyers willing to take the other side. Nectar Lifescience Ltd locked at its lower circuit of 5% on 29 Oct 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance in supply and demand.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
16-Nov-2026 | Source : BSENectar Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
Results For Quarter And Half Year Ended September 30 2026.
14-Nov-2026 | Source : BSEPlease find attached herewith Results For Quarter And Half Year Ended September 30 2026.
Board Meeting Intimation for Financial Result And Other Business Matters
06-Nov-2026 | Source : BSENectar Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 inter alia to consider and approve unaudited financial results for the period ended September 30 2026 and other business matters
Corporate Actions 
No Upcoming Board Meetings
Nectar Lifescience Ltd has declared 5% dividend, ex-date: 11 Sep 20
Nectar Lifescience Ltd has announced 1:10 stock split, ex-date: 12 Nov 08
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 9 FIIs (0.5%)
Sanjiv Goyal (24.63%)
Rajasthan Global Securities Private Limited (3.9%)
37.62%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is -97.73% vs -65.89% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 117.66% vs 77.33% in Jun 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 4.89% vs -98.68% in Sep 2024
Growth in half year ended Sep 2025 is -2,891.60% vs 201.76% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 4.78% vs -99.16% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -1,470.93% vs 272.11% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is -90.59% vs -98.73% in Mar 2025
YoY Growth in year ended Mar 2026 is -157.64% vs -2,378.16% in Mar 2025